Merck & Co. has acquired Modifi Biosciences for $30 million, with potential additional payments of up to $1.3 billion based on milestones. Meanwhile, Roche reported that sales of Sarepta's gene therapy Elevidys reached approximately $156 million outside the U.S. in the first nine months of the year. Sangamo Therapeutics is on track to file for accelerated approval of its Fabry disease treatment, while MacroGenics sold rights to its breast cancer drug Margenza for $40 million, with additional milestone payments possible.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
